Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Copurification of a Recombinant Modified Glucagon-Like and Glucose-Dependent Insulinotropic Peptide to Create a Two-Component Drug for the Treatment of Type 2 Diabetes Mellitus and Obesity

Copurification of a Recombinant Modified Glucagon-Like and Glucose-Dependent Insulinotropic... In addition to the previously developed recombinant modified human glucagon-like peptide 1 (rmGlp1, glypin), a recombinant modified human glucose-dependent insulinotropic peptide (rmGip) has been obtained. A new universal reverse-phase HPLC technique has been proposed that allows quantitative analysis of rmGlp1 and rmGip separately and as part of a two-component preparation. The design of recombinant human rmGip according to the protocols developed for glypin (the glypin formula) makes it possible to produce one-component and two-component preparations with various rmGip and rmGlp1 protein ratios ranging from 1 : 0 to 20 : 1, using cell biomass samples mixed in predetermined proportions. Studies of human rmGip activity in a mouse model revealed reduced specific activity and signs of weak antagonistic effects. In this regard, there is a need for further study of human rmGip activity in a mouse model, including the use of alternative mouse or rat rmGip. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Applied Biochemistry and Microbiology Springer Journals

Copurification of a Recombinant Modified Glucagon-Like and Glucose-Dependent Insulinotropic Peptide to Create a Two-Component Drug for the Treatment of Type 2 Diabetes Mellitus and Obesity

Download PDF
8 pages

Loading next page...
 
/lp/springer-journals/copurification-of-a-recombinant-modified-glucagon-like-and-glucose-YzRzC5xA0K

References (24)

Publisher
Springer Journals
Copyright
Copyright © Pleiades Publishing, Inc. 2022. ISSN 0003-6838, Applied Biochemistry and Microbiology, 2022, Vol. 58, No. 9, pp. 976–983. © Pleiades Publishing, Inc., 2022. Russian Text © The Author(s), 2021, published in Biotekhnologiya, 2021, Vol. 37, No. 6, pp. 74–83.
ISSN
0003-6838
eISSN
1608-3024
DOI
10.1134/s0003683822090034
Publisher site
See Article on Publisher Site

Abstract

In addition to the previously developed recombinant modified human glucagon-like peptide 1 (rmGlp1, glypin), a recombinant modified human glucose-dependent insulinotropic peptide (rmGip) has been obtained. A new universal reverse-phase HPLC technique has been proposed that allows quantitative analysis of rmGlp1 and rmGip separately and as part of a two-component preparation. The design of recombinant human rmGip according to the protocols developed for glypin (the glypin formula) makes it possible to produce one-component and two-component preparations with various rmGip and rmGlp1 protein ratios ranging from 1 : 0 to 20 : 1, using cell biomass samples mixed in predetermined proportions. Studies of human rmGip activity in a mouse model revealed reduced specific activity and signs of weak antagonistic effects. In this regard, there is a need for further study of human rmGip activity in a mouse model, including the use of alternative mouse or rat rmGip.

Journal

Applied Biochemistry and Microbiology – Springer Journals

Published: Dec 1, 2022

Keywords: type 2 diabetes mellitus; two-component drug; glucose-dependent insulinotropic peptide; glucagon-like peptide-1

There are no references for this article.